|
1
|
WHO international agency for research on
cancer: Globocan 2012: Estimated cancer incidence, mortality and
prevalence worldwide in 2012. 2012.
|
|
2
|
Joshi B, Cameron A and Jagus R:
Characterization of mammalian eIF4E-family members. Eur J Biochem.
271:2189–2203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ziemniak M, Strenkowska M, Kowalska J and
Jemielity J: Potential therapeutic applications of RNA cap analogs.
Future Med Chem. 5:1141–1172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Culjkovic B, Topisirovic I and Borden KL:
Controlling gene expression through RNA regulons: The role of the
eukaryotic translation initiation factor eIF4E. Cell Cycle.
6:65–69. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jackson RJ, Hellen CU and Pestova TV: The
mechanism of eukaryotic translation initiation and principles of
its regulation. Nat Rev Mol Cell Biol. 11:113–127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Benedetti A and Graff JR: eIF-4E
expression and its role in malignancies and metastases. Oncogene.
23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshizawa A, Fukuoka J, Shimizu S, Shilo
K, Franks TJ, Hewitt SM, Fujii T, Cordon-Cardo C, Jen J and Travis
WD: Overexpression of phospho-eIF4E is associated with survival
through AKT pathway in non-small cell lung cancer. Clin Cancer Res.
16:240–248. 2010. View Article : Google Scholar
|
|
8
|
Armengol G, Rojo F, Castellví J, Iglesias
C, Cuatrecasas M, Pons B, Baselga J and Ramón y Cajal S: 4E-binding
protein 1: A key molecular 'funnel factor' in human cancer with
clinical implications. Cancer Res. 67:7551–7555. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rojo F, Najera L, Lirola J, Jiménez J,
Guzmán M, Sabadell MD, Baselga J and Ramon y Cajal S: 4E-binding
protein 1, a cell signaling hallmark in breast cancer that
correlates with pathologic grade and prognosis. Clin Cancer Res.
13:81–89. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Graff JR, Konicek BW, Lynch RL, Dumstorf
CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop
JW, et al: eIF4E activation is commonly elevated in advanced human
prostate cancers and significantly related to reduced patient
survival. Cancer Res. 69:3866–3873. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Graff JR, Konicek BW, Carter JH and
Marcusson EG: Targeting the eukaryotic translation initiation
factor 4E for cancer therapy. Cancer Res. 68:631–634. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri
FR and Sun SY: Phosphorylated eukaryotic translation initiation
factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol
Ther. 8:1463–1469. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang B, Zhu C, Chen B, Zhang X, Ye M and
Lin A: Expression and its clinical significance of eIF4E in
non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 13:1132–1135.
2010.In Chinese. PubMed/NCBI
|
|
14
|
Li L, Lin M, Li L, Wang R, Zhang C, Qi G,
Xu M, Rong R and Zhu T: Renal telocytes contribute to the repair of
ischemically injured renal tubules. J Cell Mol Med. 18:1144–1156.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Crinò L, Weder W and van Meerbeeck J:
Early stage and locally advanced (non-metastatic) non-small-cell
lung cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 21(Suppl 5): v103–v115. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sonenberg N and Hinnebusch AG: Regulation
of translation initiation in eukaryotes: Mechanisms and biological
targets. Cell. 136:731–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rousseau D, Kaspar R, Rosenwald I, Gehrke
L and Sonenberg N: Translation initiation of ornithine
decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are
increased in cells overexpressing eukaryotic initiation factor 4E.
Proc Natl Acad Sci USA. 93:1065–1070. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Scapinello A, D'Amore ES, Cavazzana AO,
Gramegna V and Ninfo V: Retroperitoneal cystic neuroendocrine
tumor. A case report. Pathologica. 87:544–547. 1995.PubMed/NCBI
|
|
19
|
Graff JR and Zimmer SG: Translational
control and metastatic progression: Enhanced activity of the mRNA
cap-binding protein eIF-4E selectively enhances translation of
metastasis-related mRNAs. Clin Exp Metastasis. 20:265–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Topisirovic I, Ruiz-Gutierrez M and Borden
KL: Phosphorylation of the eukaryotic translation initiation factor
eIF4E contributes to its transformation and mRNA transport
activities. Cancer Res. 64:8639–8642. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Phillips A and Blaydes JP: MNK1 and EIF4E
are downstream effectors of MEKs in the regulation of the nuclear
export of HDM2 mRNA. Oncogene. 27:1645–1649. 2008. View Article : Google Scholar
|
|
22
|
Wendel HG, Silva RL, Malina A, Mills JR,
Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J,
Pelletier J and Lowe SW: Dissecting eIF4E action in tumorigenesis.
Genes Dev. 21:3232–3237. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ruggero D, Montanaro L, Ma L, Xu W, Londei
P, Cordon-Cardo C and Pandolfi PP: The translation factor eIF-4E
promotes tumor formation and cooperates with c-Myc in
lymphomagenesis. Nat Med. 10:484–486. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wendel HG, De Stanchina E, Fridman JS,
Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J and Lowe SW:
Survival signalling by Akt and eIF4E in oncogenesis and cancer
therapy. Nature. 428:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bremaud A, West DC and Thomson AM:
Binomial parameters differ across neocortical layers and with
different classes of connections in adult rat and cat neocortex.
Proc Natl Acad Sci USA. 104:14134–14139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ueda T, Sasaki M, Elia AJ, Chio II, Hamada
K, Fukunaga R and Mak TW: Combined deficiency for MAP
kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor
development. Proc Natl Acad Sci USA. 107:13984–13990. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Graff JR, Konicek BW, Vincent TM, Lynch
RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS,
et al: Therapeutic suppression of translation initiation factor
eIF4E expression reduces tumor growth without toxicity. J Clin
Invest. 117:2638–2648. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jacobson BA, Thumma SC, Jay-Dixon J, Patel
MR, Dubear Kroening K, Kratzke MG, Etchison RG, Konicek BW, Graff
JR and Kratzke RA: Targeting eukaryotic translation in mesothelioma
cells with an eIF4E-specific antisense oligonucleotide. PLoS One.
8:e816692013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ramalingam S, Gediya L, Kwegyir-Afful AK,
Ramamurthy VP, Purushottamachar P, Mbatia H and Njar VC: First MNKs
degrading agents block phosphorylation of eIF4E, induce apoptosis,
inhibit cell growth, migration and invasion in triple negative and
Her2-overexpressing breast cancer cell lines. Oncotarget.
5:530–543. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Konicek BW, Stephens JR, McNulty AM,
Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons
S, Ellis KE, et al: Therapeutic inhibition of MAP kinase
interacting kinase blocks eukaryotic initiation factor 4E
phosphorylation and suppresses outgrowth of experimental lung
metastases. Cancer Res. 71:1849–1857. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kentsis A, Topisirovic I, Culjkovic B,
Shao L and Borden KL: Ribavirin suppresses eIF4E-mediated oncogenic
transformation by physical mimicry of the 7-methyl guanosine mRNA
cap. Proc Natl Acad Sci USA. 101:18105–18110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Assouline S, Culjkovic B, Cocolakis E,
Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH
Jr and Borden KL: Molecular targeting of the oncogene eIF4E in
acute myeloid leukemia (AML): A proof-of-principle clinical trial
with ribavirin. Blood. 114:257–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moerke NJ, Aktas H, Chen H, Cantel S,
Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, et
al: Small-molecule inhibition of the interaction between the
translation initiation factors eIF4E and eIF4G. Cell. 128:257–267.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang SX, Hewitt SM, Steinberg SM, Liewehr
DJ and Swain SM: Expression levels of eIF4E, VEGF, and cyclin D1,
and correlation of eIF4E with VEGF and cyclin D1 in multitumor
tissue microarray. Oncol Rep. 17:281–287. 2007.PubMed/NCBI
|
|
35
|
Helkkinen T, Korpela T, Fagerholm R, Khan
S, Aittomäki K, Heikkilä P, Blomqvist C, Carpén O and Nevanlinna H:
Eukayrotic translation initiation factor 4E (eIF4E) expression is
associated with breast cancer treatment phenotype and predicts
survival after anthracycline chemotherapy treatment. Breast Cancer
Res Treat. 141:79–88. 2013. View Article : Google Scholar
|
|
36
|
Liang S, Guo R, Zhang Z, Liu D, Xu H, Xu
Z, Wang X and Yang L: Upregulation of the eIF4E signaling pathway
contributes to the progression of gastric cancer, and targeting
eIF4E by perifosine inhibits cell growth. Oncol Rep. 29:2422–2430.
2013.PubMed/NCBI
|
